A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants | MicrobiomeTrials
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-01-15Est. Completion: 2026-09-30
Enrollment target: 215 participants
Locations
GSK Investigational Site, Kumasi, Ghana
Other microbiome trials you might be interested in